Lv11
40 积分 2024-07-05 加入
Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046)
6小时前
待确认
DNA Damage Repair Inhibitors—Combination Therapies
6天前
已完结
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options
10天前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
19天前
已完结
Synergistic Strategies: ADC-PARP Inhibitor Combinations in Triple-Negative Breast Cancer Therapy
24天前
已关闭
Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer
29天前
已完结
Triptolide-based cleavable antibody-drug conjugates for pancreatic cancer
29天前
已完结
The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial
29天前
已完结
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
1个月前
已完结
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
1个月前
已完结
皖公网安备34019202002308
